Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis

Cutis

Volumn 86, Issue 4, 2010, Pages 208-213

  Yentzer, Brad A ^a   Ade, Rachel A ^a   Fountain, Julie M ^a   Clark, Adele R ^a   Taylor, Sarah L ^a   Borgerding, Erika ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINONIDE; GLUCOCORTICOID;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PATIENT COMPLIANCE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DERMATITIS, ATOPIC; FEMALE; FLUOCINONIDE; GLUCOCORTICOIDS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650616724     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Schmitt J, Heese E, Wozel G, et al. Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris-a prospective study. Dermatology. 2007;214:68-76.
2. Miller JJ, Roling D, Margolis D, et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol. 1999;41: 546-549.
3. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-216.
4. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56:211-216.
5. Ali SM, Brodell RT, Balkrishnan R, et al. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007;143:912-915.
6. Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement. implications for dermatology. Am J Clin Dermatol. 2001;2:7-12.
7. Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharmaceut Econ. 1990;2(2):19-33.
8. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150: 1377-1378.
9. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57:81-83.
10. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10: 11-18.
11. Yentzer BA, Camacho FT, Young T, et al. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. J Drugs Dermatol. 2010;9:324-329.
12. Wilson R, Camacho F, Clark AR, et al. Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis. J Am Acad Dermatol. 2009;60:166-168.